Lilly’s Alzheimer’s drug shows benefit of their medicines

Promotions

Date: 01.04.2021

Eli Lilly and Co on Saturday said its experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32% compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease.

The drug, donanemab, also showed positive trends that failed to reach statistical significance on a range of secondary trial goals, the company said, providing details for the first time.

The 18-month, 272-patient study showed, for instance, that patients treated with donanemab had a 23% slower rate of decline in a measure known as the Clinical Dementia Rating Scale Sum of Boxes, a tool commonly used to gauge dementia severity.

The ability to carry out activities like dressing and eating is often impacted by Alzheimer’s disease, which reduces cognitive ability like memory and language.

Donanemab is an antibody designed to remove clumps of the Alzheimer’s-related protein beta amyloid from the brain. It targets a specific type of beta amyloid that Lilly believes can be rapidly cleared, enabling short-term, but durable treatment.

Patients in the study stopped receiving donanemab and were switched to placebo once their brain plaques reached levels seen in healthy people. Beta amyloid has been a popular target for dozens of experimental Alzheimer’s drugs, all of which have failed so far.

The article was prepared based on the information: Reuters

Views: 8

Leave a request

Select option
Thank you, application submitted.